asco.org2 天
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A ...
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org2 天
Feasibility of pharmacist co-management for patients prescribed oral anticancer therapy for ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Cost differential among systemic therapies for colon cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Combination immunotherapy selection for non-PD-1 axis driven tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...